Labiotech.eu

This week, Labiotech was attending the Nordic Life Science Days! 💡   The event took place on October 13 and 14 in Gothenburg a dynamic region of Sweden, catching up with the Stockholm area as a Life science cluster. Indeed, Gothenburg is the scene where the AstraZeneca BioVentureHub experiment started in 2014. A bit over ten years later, the hub is thriving and has become a vertical ecosystem around Life Sciences. 🚀 Jules ADAM from Labiotech had the opportunity to talk to Magnus Björsne, CEO of the hub, and many other players of the ecosytem. 💬    Read the article below! 👇️  https://lnkd.in/duZ5ic-G #NLSDays #SwedenBiotech #lifesciences #biotechinnovation #nordicbiotech #biotechevents #startupecosystem #healthcareinnovation #biotechcommunity Lorenzo Roversi IonQ

Biotech royalty deals have been on the rise for a while now... 📈 🚀 HealthCare Royalty are among the pioneers in royalty-based financing, with a thirty-year track record in biopharma investing.  💬 In today’s episode of the Beyond Biotech Podcast, Labiotech’s Dylan Kissane sat down with HealthCare Royalty Partners’ CEO and chairman Clarke Futch, who has led more than 60 royalty acquisitions totaling nearly $4 billion and raised over $8 billion across various vehicles. 💰 Clark gave his insights on the evolution of alternative funding models and its impact on biotech innovation, partnerships, and M&A. 💡 🎧 Tune in to find out more! 👇  https://lnkd.in/dtzbxDH3 #BeyondBiotechPodcast #lifesciences #venturecapital #biotechinnovation #drugdevelopment #biotechgrowth

💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Kailera Therapeutics | $600 million series B | GLP-1 therapies | phase 3-ready in obesity 🇺🇸 Apogee Therapeutics | $345 million public offering | antibody therapies | phase 2 in atopic dermatitis 🇺🇸 Spyre Therapeutics | $275 million public offering | antibody therapies | phase 2 in inflammatory bowel disease 🇺🇸 Kardigan | $254 million series B | personalized cardiovascular medicines | lead asset for dilated cardiomyopathy  🇺🇸 Soufflé Therapeutics | $200 million series A | siRNA medicines | lead programs for facioscapulohumeral muscular dystrophy, cardiomyopathies, and metabolism 🇺🇸 Expedition Therapeutics | $165 million series A | respiratory disease therapies | phase 2-ready in COPD 🇺🇸 Arthrosi Therapeutics, Inc. | $153 million series E | URAT1 inhibitor | phase 3 in gout  🇺🇸 Nilo Therapeutics | $101 million series A | neural circuit-targeting medicines | preclinical in autoimmune and inflammatory diseases      🇺🇸 Excellergy | $70 million series A | trifunctional effector cell response inhibitors for allergic control 🇺🇸 Tr1X | $50 million financing | cell therapies | phase 1/2a in Crohn’s disease   🇺🇸 Annovis Bio, Inc. Bio | $6 million registered direct offering | neurodegenerative disease therapies | phase 3 in Alzheimer’s disease Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

💸⌛ There's not long left to win a $100 gift voucher through Inpart's biopharma partnering survey (in collaboration with Evaluate Ltd)! If you work with pharma companies to out-license innovation, don’t miss this opportunity to be rewarded for sharing your recent partnering experiences. Join over 250 other out-licensors to help shape an industry-wide report on: 🔹 The biggest challenges in securing the right pharma partners 🔹 How AI is changing dealmaking 🔹 The most effective channels for making meaningful connections What’s in it for you? 🎁 Entry into a draw to win 1 of 5 x $100 vouchers 📘 An eBook on conference partnering best practices 📊 Evaluate’s annual partnering report The survey takes around 15 mins to complete, and all results are fully anonymized. 👉 Take the survey now: https://lnkd.in/dtp-Hmmi #Partnering2030 #Biopharma #LifeSciences #PharmaPartnering #Biotech #BusinessDevelopment #OutLicensing #EvaluatePharma #PharmaInnovation

The heart of the UK’s Golden Triangle: A closer look at Cambridge’s biotech hub.

Have you heard of these five biotechs in Luxembourg that are making a name for themselves? 🇱🇺 One of the wealthiest countries in the world, Luxembourg is renowned for its gromperekichelcher, fine wines, and medieval castles. 🏰 An economic powerhouse in Europe, the country’s health tech sector is mainly focused on the manufacture of diagnostic and medical devices, while the biopharma industry, is gradually growing.  🌱 Read our latest article on five biotechs that are flourishing in Luxembourg! 👇  https://lnkd.in/dz99BKC5  #LuxembourgBiotech #lifesciences #healthtech #startupecosystem #biotechstartups #drugdiscovery #healthcareinnovation    Exobiosphere House of Biohealth Mitotech NIUM  OrganoTherapeutics Tolerogenics S.à.r.l. Luxbiotech Corporate

🤖🧬 As artificial intelligence (AI) becomes ever more integrated into the world of biotech, one of its latest applications is the discovery and design of peptides – a rapidly emerging field that uses machine learning and deep learning to accelerate the discovery, de novo design, and optimization of peptides for areas like healthcare, food and cosmetics. 💊🍽️💄   As peptide drugs become increasingly popular with biotech and pharma companies, it is likely that the use of AI to discover and design them will also become the norm. Could this in turn signal the beginning of a golden age for peptides? ✨ To find out more, read our latest article by Willow Shah-Neville! 👇  https://lnkd.in/djigxFdf  #peptidetherapeutics #machinelearning #deeplearning #biotechinnovation #lifesciences #healthcareinnovation #AIinbiotech Dr. Nora K. Nuritas

What therapies are in line to address Prader-Willi syndrome? 🔮   🧬 Prader-Willi syndrome is a rare genetic condition that is characterized by various physical, mental, and behavioral issues. One of the most common symptoms is hyperphagia, which is a feeling of extreme, insatiable hunger. 🍽️ This year, the first-ever medicine to address hyperphagia in patients with Prader-Willi, VYKAT XR, was approved by the FDA. ✅ There are several clinical trials testing different therapies that could address a host of symptoms in patients. 🏥 Read our latest article to learn about five much-anticipated treatments poised for approval! 👇  https://lnkd.in/dKPgGxGJ #PraderWilliSyndrome #raredisease #geneticdisorders #biotech #drugdevelopment #genetherapy #neuroscience #biopharma #lifesciences #medicalinnovation   Aardvark Therapeutics Rhythm Pharmaceuticals Inc. Palobiofarma S.L. Tonix Pharmaceuticals Harmony Biosciences Foundation For Prader-Willi Research Montefiore

Explore what’s next in pharma at CPHI Frankfurt 2025. Join thousands of professionals from across the global pharmaceutical supply chain 28th–30th October at Messe Frankfurt. From cutting-edge innovation to industry-wide collaboration, this is your opportunity to build connections and drive change. 🔗 Why attend: https://lnkd.in/gge_U-XW #CPHIFrankfurt #AtTheHeartOfPharma #Pharma CPHI

Forming part of the UK’s “Golden Triangle”, Cambridge has a reputation as a leading biotech hub thanks to its strong concentration of academic and research institutions, a rich talent pipeline, a thriving cluster of biotech startups and established companies, and a significant flow of investment. 💡💰 Of course, there are other biotech hubs across Europe and North America that are similarly connected to world-class academic institutions and located alongside leading industry players. So, what is it that makes Cambridge so special? 🤔✨  To find out more, read our latest article by Willow Shah-Neville! 👇  https://lnkd.in/dyBrJzrT #biotech #lifesciences #innovation #biotechhub #biotechstartups #biotechinvestment #science   Ola (Aleksandra) Wlodek Constructive Bio